

Appendix 2

Rate ratio estimates (RR) of venous thromboembolism (VTE) between users of different combined oral contraceptives with 30-40 ug ethinylestradiol (EE) according different steps in exposure line formation

2001-May 2007* COC with	Women-years n / n	VTE all n / n	Adjust RR ¹	95% CI		p-value
				Low	High	
Raw exposure lines						
DRSP vs LNG	207,270 / 157,383	187 / 112	2.18	1.72	2.77	<.0001
DRSP vs 3rd gen	207,270 / 607,557	187 / 632	1.11	0.94	1.32	0.199
Desogestrel vs LNG	122,309 / 157,383	124 / 112	1.80	1.40	2.33	<.0001
Gestodene vs LNG	485,248 / 157,383	508 / 112	2.00	1.63	2.46	<.0001
Gap-corrected exposure lines						
DRSP vs LNG all	221,190 / 165,248	197 / 118	2.17	1.72	2.74	<.0001
DRSP vs 3rd gen	221,190 / 641,780	197 / 660	1.12	0.95	1.31	0.178
Desogestrel vs LNG	129,609 / 165,248	133 / 118	1.83	1.43	2.35	<.0001
Gestodene vs LNG	512,171 / 165,248	527 / 118	1.98	1.62	2.42	<.0001
Switch corrected exposure lines						
DRSP vs LNG	217,372 / 163,856	197 / 118	2.19	1.74	2.77	<.0001
DRSP vs 3rd gen	217,372 / 637,084	197 / 657	1.13	0.96	1.33	0.130
Desogestrel vs LNG	128,241 / 163,856	133 / 118	1.84	1.43	2.35	<.0001
Gestodene vs LNG	508,843 / 163,856	524 / 118	1.96	1.60	2.40	<.0001

*) 2001-May 2007 was chosen due to a media event in June 2007 after which many women switched from COC with drospirenone.

1) Adjust RR: Adjusted for age, year and education.

LNG = COC with levonorgestrel phasic + combined and 30-40 µg EE..

Desogestrel = COC with desogestrel and 30 µg EE.

Gestodene = COC with gestodene and 30 µg EE

DRSP = COC with drospirenone and 30 µg EE.

3rd gen = COC with third generation progestogens (desogestrel or gestodene) and 30 µg EE